Dasatinib
ph+ Acute Lymphoblastic Leukemia
University of ChicagoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the ph+ Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS University of Chicago | Phase 2 | CCC |
MERCAPTOPURINE ANHYDROUS University of Chicago | Phase 2 | CCC |
Inotuzumab Ozogamicin University of Chicago | Phase 2 | CCC |
METHOTREXATE University of Chicago | Phase 2 | CCC |
DEXAMETHASONE University of Chicago | Phase 2 | CCC |
(+)-VINCRISTINE University of Chicago | Phase 2 | CCC |
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →